Literature DB >> 34760968

Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: a propensity score matching analysis.

Zhen-Hua Chen1, Xiu-Ping Zhang1,2, Shuang Feng3, Jing-Kai Feng1, Zong-Tao Chai1, Wei-Xing Guo1, Jie Shi1, Wan Yee Lau1,4, Yan Meng3, Shu-Qun Cheng1.   

Abstract

BACKGROUND: The presence of hepatic vein tumor thrombus (HVTT) is a major determinant of survival outcomes in hepatocellular carcinoma (HCC) patients. This study compared survival outcomes between liver resection (LR) and intensity-modulated radiation therapy (IMRT) in HCC patients with HVTT.
METHODS: Data from patients who underwent LR or IMRT for HCC with HVTT at the Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed. Their survival outcomes were compared before and after propensity score matching (PSM).
RESULTS: Three hundred and seven HCC patients with HVTT who underwent either LR (n=140) or IMRT (n=167) were enrolled. PSM matched 82 pairs of patients. The overall survival (OS) and recurrence-free survival (RFS) rates were significantly higher for patients in the LR group than those in the IMRT group. On subgroup analysis, significantly better survival outcomes were obtained after LR than IMRT in patients with peripheral type of HVTT (pHVTT) and major type of HVTT (mHVTT). However, similar survival outcomes were obtained after LR and IMRT when the HVTT had developed into inferior vena cava tumor thrombus (IVCTT).
CONCLUSIONS: LR resulted in significantly better survival outcomes in HCC patients with HVTT when compared to IMRT. Once the HVTT had developed IVCTT, LR and IMRT resulted in similarly bad survival outcomes. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); hepatic vein tumor thrombus (HVTT); liver resection (LR); radiotherapy

Year:  2021        PMID: 34760968      PMCID: PMC8527405          DOI: 10.21037/hbsn.2020.03.20

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   8.265


  38 in total

1.  A new classification for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Jie Shi; Eric C H Lai; Nan Li; Wei-Xing Guo; Jie Xue; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-01       Impact factor: 7.027

2.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

3.  Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial.

Authors:  Françoise Mornex; Nicolas Girard; Christophe Beziat; Abdul Kubas; Mustapha Khodri; Christian Trepo; Philippe Merle
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-15       Impact factor: 7.038

4.  Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study.

Authors:  Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Iwao Ikai; David M Nagorney; Jacques Belghiti; Reza Kianmanesh; Irene Oi-Lin Ng; Steven A Curley; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey
Journal:  Surgery       Date:  2005-04       Impact factor: 3.982

5.  A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus.

Authors:  Zhao-Chong Zeng; Jia Fan; Zhao-You Tang; Jian Zhou; Lun-Xiu Qin; Jian-Hua Wang; Hui-Chuan Sun; Bin-Liang Wang; Jian-Ying Zhang; Guo-Liang Jiang; Yu-Qi Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

6.  Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution.

Authors:  Ryosuke Nakano; Masahiro Ohira; Tsuyoshi Kobayashi; Kentaro Ide; Hiroyuki Tahara; Shintaro Kuroda; Seiichi Shimizu; Tomoki Kimura; Yasushi Nagata; Hiroshi Aikata; Kazuaki Chayama; Hideki Ohdan
Journal:  Surgery       Date:  2018-05-23       Impact factor: 3.982

7.  Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava.

Authors:  Eisuke Murakami; Hiroshi Aikata; Daisuke Miyaki; Yuko Nagaoki; Yoshio Katamura; Tomokazu Kawaoka; Shintaro Takaki; Akira Hiramatsu; Koji Waki; Shoichi Takahashi; Tomoki Kimura; Masahiro Kenjo; Yasushi Nagata; Masaki Ishikawa; Hideaki Kakizawa; Kazuo Awai; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2011-12-16       Impact factor: 4.288

8.  Aggressive resection of hepatocellular carcinoma with right atrial involvement.

Authors:  Sander Florman; Michael Weaver; Paul Primeaux; Mary Killackey; Rafael Sierra; Santiago Gomez; Salima Haque; Fredric Regenstein; Luis Balart
Journal:  Am Surg       Date:  2009-11       Impact factor: 0.688

9.  Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein.

Authors:  Hyo-Cheol Kim; Jeong-Hoon Lee; Jin Wook Chung; Beomsik Kang; Jung-Hwan Yoon; Yoon Jun Kim; Hyo-Suk Lee; Hwan Jun Jae; Jae Hyung Park
Journal:  J Vasc Interv Radiol       Date:  2013-01-28       Impact factor: 3.464

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

View more
  2 in total

1.  Beyond management to conquer life-threatening tumor thrombosis in hepatocellular carcinoma.

Authors:  Hironori Koga
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

2.  PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.

Authors:  Ke Su; Lu Guo; Wenqiong Ma; Jing Wang; Yunchuan Xie; Mingyue Rao; Jianwen Zhang; Xueting Li; Lianbin Wen; Bo Li; Xiaoli Yang; Yanqiong Song; Weihong Huang; Hao Chi; Tao Gu; Ke Xu; Yanlin Liu; Jiali Chen; Zhenying Wu; Yi Jiang; Han Li; Hao Zeng; Pan Wang; Xunjie Feng; Siyu Chen; Binbin Yang; Hongping Jin; Kun He; Yunwei Han
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.